Abstract
The atypical antipsychotic cariprazine was more effective than placebo in improving depressive symptoms in a Phase 3 study involving adults with bipolar disorder and a current depressive episode. Both 1.5 mg/day and 3 mg/day doses of the drug were found to be relatively safe and effective, researchers reported. Study results were published online March 8 in the American Journal of Psychiatry.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have